Resources Repository
-
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Oceania | Asia & Pacific | Mental Health | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Health/Medicine -
ArticlePublication 2016Funding Gap for Immunization Across 94 Low- and Middle-Income Countries
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 …
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 low- and middle-income countries over the five-year period of 2016–2020. Vaccine financing by country governments, GAVI, and other development sources was forecasted for vaccine, supply chain, and service delivery based on an analysis of comprehensive multi-year plans together with a series of scenarios. The authors found that that delivery of full vaccination programs across the 94 countries would result in a total…
Asia & Pacific | Latin America & Caribbean | Global Governance | Infectious Diseases | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Asia & Pacific | Latin America & Caribbean | Global Governance | Infectious Diseases | Mathematical Models | Dynamic Transmission | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Climate/Environment | Economics/Finance | Health/Medicine -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Asia & Pacific | Latin America & Caribbean | Global Governance | Infectious Diseases | Health Outcomes | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa -
ArticlePublication 2023Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection
The objective of this study was to evaluate the performance of rapid antigen tests (Ag-RDTs) …
The objective of this study was to evaluate the performance of rapid antigen tests (Ag-RDTs) for detection of SARS-CoV-2 among symptomatic and asymptomatic participants. The general findings were that the performance of Ag-RDTs was optimized when asymptomatic participants tested 3 times at 48-hour intervals and when symptomatic participants tested 2 times separated by 48 hours. Participants completed Ag-RDTs and reverse transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 every 48 hours for 15 days. They…
North America | Clinical Care | Infectious Diseases | Test Performance | Health/Medicine | Science/Technology -
ArticlePublication 2020Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure
This study aimed to determine the false-negative rate of RT-PCR tests for SARS-CoV-2 infection based …
This study aimed to determine the false-negative rate of RT-PCR tests for SARS-CoV-2 infection based on the timeline of exposure and symptom onset. Drawing from data in seven studies involving 1,330 upper respiratory tract samples, a Bayesian model was used to estimate these rates. Findings showed that in the initial four days prior to typical symptom onset, the false-negative rate decreased from 100% on day 1 to 67% on day 4. By the day of…
North America | Clinical Care | Infectious Diseases | Test Performance | Health/Medicine | Science/Technology -
ReviewPublication 2021Considerations for Diagnostic COVID-19 Tests
During the initial stages of the COVID-19 pandemic, there was a rush by numerous diagnostic …
During the initial stages of the COVID-19 pandemic, there was a rush by numerous diagnostic test manufacturers to create, validate, and implement testing methods. This review discusses the pivotal role of diagnostic tests during the pandemic's first global wave, highlighting the challenges in technology and implementation experienced early on. The study also offers insights for enhancing the use of diagnostics, especially syndromic ones, should there be future spikes or regional outbreaks of COVID-19. The overarching…
North America | Clinical Care | Infectious Diseases | Test Performance | Health/Medicine | Science/Technology -
ArticlePublication 2022Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 …
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 billion in March 2021 for testing in schools. The study aimed to analyze the costs and benefits of different COVID-19 testing strategies, particularly focusing on full-time, in-person elementary and middle school education. Utilizing an updated agent-based network model, the study simulated transmission scenarios in schools, considering various testing strategies ranging from diagnostic testing (test-to-stay) to reduce symptom-based isolations, routine screening…
North America | Clinical Care | Infectious Diseases | Test Performance | Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Science/Technology -
ReviewPublication 2022Rapid, Point-of-Care Antigen Tests for Diagnosis of SARS-CoV-2 Infection
This study reviewed the diagnostic accuracy of rapid, point-of-care antigen tests for detecting SARS-CoV-2 infection, …
This study reviewed the diagnostic accuracy of rapid, point-of-care antigen tests for detecting SARS-CoV-2 infection, differentiating results between symptomatic and asymptomatic individuals. Using data from 155 study cohorts, the study found that the sensitivity of antigen tests was generally higher for symptomatic individuals, especially during the first week after symptom onset, due to higher viral loads. For example, average sensitivity was higher in symptomatic (73.0%) compared to asymptomatic participants (54.7). Average sensitivity was higher in…
North America | Clinical Care | Infectious Diseases | Test Performance | Health/Medicine | Science/Technology